What do systematic reviews say?

Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Clinical improvement: discharged alive ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Hospital‐acquired infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Invasive fungal infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Improvement of clinical status: time to symptom resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…

Progression‐free survival · women with advanced EOC after primary IDS

Adverse effect: cataract · people with dry eye

Change in patient‐reported quality of life scores · people with dry eye

Change in patient‐reported quality of life scores · people with dry eye

Neurodevelopmental disability · preterm infants receiving nasal CPAP

Hypertension ‐ not measured · children (2 to < 18 years) in the general population

Blood pressure control ‐ not measured · children (2 to < 18 years) in the general population